<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="description" content="drugdevelopR">
<title>Binary Distributed Outcome Variables • drugdevelopR</title>
<script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.2.2/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.2.2/bootstrap.bundle.min.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- bootstrap-toc --><script src="https://cdn.jsdelivr.net/gh/afeld/bootstrap-toc@v1.0.1/dist/bootstrap-toc.min.js" integrity="sha256-4veVQbu7//Lk5TSmc7YV48MxtMy98e26cf5MrgZYnwo=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- search --><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="Binary Distributed Outcome Variables">
<meta property="og:description" content="drugdevelopR">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>
    

    <nav class="navbar fixed-top navbar-light navbar-expand-lg bg-light"><div class="container">
    
    <a class="navbar-brand me-2" href="../index.html">drugdevelopR</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.1.0</small>

    
    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="nav-item">
  <a class="nav-link" href="../reference/index.html">Reference</a>
</li>
<li class="active nav-item dropdown">
  <a href="#" class="nav-link dropdown-toggle" data-bs-toggle="dropdown" role="button" aria-expanded="false" aria-haspopup="true" id="dropdown-articles">Articles</a>
  <div class="dropdown-menu" aria-labelledby="dropdown-articles">
    <a class="dropdown-item" href="../articles/Bias_adjustment.html">Methods for Discounting of Phase II Results - Bias Adjustment</a>
    <a class="dropdown-item" href="../articles/Binary_distributed_outcomes.html">Binary Distributed Outcome Variables</a>
    <a class="dropdown-item" href="../articles/Fixed_and_prior_distributions.html">Fixed effects and prior distributions</a>
    <a class="dropdown-item" href="../articles/Interpreting_Output.html">Interpreting the Rest of the Output</a>
    <a class="dropdown-item" href="../articles/More_Parameters.html">More Parameters to Adapt to Specific Settings and Individual Needs</a>
    <a class="dropdown-item" href="../articles/Multiarm_Trials.html">Multiarm_Trials</a>
    <a class="dropdown-item" href="../articles/Multiple_Endpoints.html">Multiple_Endpoints</a>
    <a class="dropdown-item" href="../articles/Multitrial.html">Multitrial Programs - Methods for Programs with Several Phase III Trials</a>
    <a class="dropdown-item" href="../articles/Time-to-event_outcomes.html">Time-to-event Outcome Variables</a>
    <a class="dropdown-item" href="../articles/introduction-to-drugdevelopR.html">Introduction to planning phase II and phase III trials with drugdevelopR</a>
  </div>
</li>
<li class="nav-item">
  <a class="nav-link" href="../news/index.html">Changelog</a>
</li>
      </ul>
<form class="form-inline my-2 my-lg-0" role="search">
        <input type="search" class="form-control me-sm-2" aria-label="Toggle navigation" name="search-input" data-search-index="../search.json" id="search-input" placeholder="Search for" autocomplete="off">
</form>

      <ul class="navbar-nav">
<li class="nav-item">
  <a class="external-link nav-link" href="https://github.com/Sterniii3/drugdevelopR/" aria-label="github">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul>
</div>

    
  </div>
</nav><div class="container template-article">




<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">
      <img src="" class="logo" alt=""><h1>Binary Distributed Outcome Variables</h1>
                        <h4 data-toc-skip class="author">Johannes
Cepicka</h4>
            
      
      <small class="dont-index">Source: <a href="https://github.com/Sterniii3/drugdevelopR/blob/HEAD/vignettes/Binary_distributed_outcomes.Rmd" class="external-link"><code>vignettes/Binary_distributed_outcomes.Rmd</code></a></small>
      <div class="d-none name"><code>Binary_distributed_outcomes.Rmd</code></div>
    </div>

    
    
<p>Suppose we are planning a drug development program testing the
superiority of an experimental treatment over a control treatment. Our
drug development program consists of an exploratory phase II trial which
is, in case of promising results, followed by a confirmatory phase III
trial.</p>
<p>The drugdevelopR package enables us to optimally plan such programs
using a utility-maximizing approach. To get a brief introduction, we
presented a very basic example on how the package works in <a href="https://sterniii3.github.io/drugdevelopR/articles/introduction-to-drugdevelopR.html">Introduction
to planning phase II and phase III trials with drugdevelopR</a>. In the
introduction, the observed outcome variable “tumor growth” was normally
distributed. However, the drugdevelopR package is not only restricted to
normally distributed outcome variables but also binary distributed
outcome variables and a time-to-event outcome variables. In this article
we want explain how the setting with binary distributed variables
works.</p>
<div class="section level2">
<h2 id="the-example-setting">The example setting<a class="anchor" aria-label="anchor" href="#the-example-setting"></a>
</h2>
<p>Suppose we are developing a new treatment to prevent strokes,
<em>exper</em>. The patient variable that we want to investigate is if
the patient has had a stroke (unfavorable outcome with value 1) or not
(favourable outcome with value 0) over a pre-defined observation period.
This is a binary distributed outcome variable.</p>
<p>Within our drug development program, we will compare our experimental
treatment <em>exper</em> to the control treatment <em>contro</em>. The
treatment effect measure is given by $ = −(RR)$, which is the negative
logarithm of the risk ratio (relative risk) <span class="math inline">\(RR = \frac{p_1}{p_0}\)</span>. Here, <span class="math inline">\(p_1\)</span> is the failure probability of the
experimental treatment (i.e. <span class="math inline">\(\mathbb{P}(X_i
= 1)\)</span>, the probability that patient <span class="math inline">\(X_i\)</span> has a stroke) and analogously <span class="math inline">\(p_0\)</span> is the failure probability of the
control treatment.</p>
</div>
<div class="section level2">
<h2 id="applying-the-package-to-the-example">Applying the package to the example<a class="anchor" aria-label="anchor" href="#applying-the-package-to-the-example"></a>
</h2>
<p>After installing the package according to the <a href="https://sterniii3.github.io/drugdevelopR/#Installation">installation
instructions</a>, we can load it using the following code:</p>
<div class="sourceCode" id="cb1"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="kw"><a href="https://rdrr.io/r/base/library.html" class="external-link">library</a></span><span class="op">(</span><span class="va"><a href="https://github.com/Sterniii3/drugdevelopR" class="external-link">drugdevelopR</a></span><span class="op">)</span></span>
<span><span class="co">#&gt; Loading required package: mvtnorm</span></span>
<span><span class="co">#&gt; Loading required package: doParallel</span></span>
<span><span class="co">#&gt; Loading required package: foreach</span></span>
<span><span class="co">#&gt; Loading required package: iterators</span></span>
<span><span class="co">#&gt; Loading required package: parallel</span></span>
<span><span class="co">#&gt; Loading required package: msm</span></span>
<span><span class="co">#&gt; Loading required package: cubature</span></span>
<span><span class="co">#&gt; Loading required package: MASS</span></span></code></pre></div>
<div class="section level3">
<h3 id="defining-all-necessary-parameters">Defining all necessary parameters<a class="anchor" aria-label="anchor" href="#defining-all-necessary-parameters"></a>
</h3>
<p>In order to apply the package to the setting from our example, we
need to specify the following parameters:</p>
<ul>
<li>
<code>p11</code> is the probability that the unfavorable outcome
occurs for our experimental treatment <em>exper</em> and <code>p0</code>
is the probability that the unfavorable outcome occurs for our control
treatment <em>contro</em>. Lets assume, that 30% of patients, who
receive the experimental treatment have a stroke and 50% of the control
group. Therefore, we set <code>p11 = 0.3</code> and
<code>p0 = 0.5</code>. For now, we will assume that the probabilities
are fixed and independent of any prior distribution. Thus, we will set
<code>fixed = TRUE</code>.</li>
<li>
<code>n2min</code> and <code>n2max</code> specify the minimal and
maximal number of participants for the phase II trial. The package will
search for the optimal sample size within this region. For now, we want
the program to search for the optimal sample size in the interval
between 20 and 400 participants. In addition, we will tell the program
to search this region in steps of four participants at a time by setting
<code>stepn2 = 4</code>.</li>
<li>
<code>rrgomin</code> and <code>rrgomax</code> specify the minimal
and maximal threshold value for the go/no-go decision rule in terms of
the negative logarithm of the risk ratio. The package will search for
the optimal threshold value within this region. For now, we want the
program to search in the interval between 0.7 and 0.9 while going in
steps of <code>steprrgo = 0.01</code>. Note, that he lower bound of the
decision rule set for represents the smallest size of treatment effect
observed in phase II allowing to go to phase III, so it can be used to
model the minimally clinically relevant effect size. Moreover, note that
the interval specified above corresponds to the set <span class="math inline">\(\{-\log(0.9), ..., -\log(0.7)\}\)</span>.</li>
<li>
<code>c02</code> and <code>c03</code> are fixed costs for phase II
and phase III respectively. We will set the phase II costs to 100 and
the phase III costs to 150 (in <span class="math inline">\(10^5\)</span>$), i.e we have fixed costs of 10 000
000$ in phase II and 15 000 000$ in phase III. Note that the currency of
the input values does not matter, so an input value for <code>c02</code>
of 15 could also be interpreted as fixed costs of 1 500 000€ if
necessary.</li>
<li>
<code>c2</code> and <code>c3</code> are the costs in phase II and
phase III per patient. We will set them to be 0.75 in phase II and 0.1
in phase III. Again, these values are given in <span class="math inline">\(10^5\)</span>$, i.e we have per patient costs of
75 000$ in phase II and 100 000$ in phase III.</li>
<li>
<code>b1</code>, <code>b2</code> and <code>b3</code> are the
expected small, medium and large benefit categories for successfully
launching the treatment on the market for each effect size category in
<span class="math inline">\(10^5\)</span>$. We will define a small
benefit of 1000, a medium benefit of 2000, and a large benefit of 3000.
The effect size categories directly correspond to the treatment effect,
i.e. if the the treatment effect is between 1 and 0.95 (in terms of the
risk ratio) we have a small treatment effect, hence yielding expected
benefits of the drug development program of 100 000 000$.</li>
<li>
<code>alpha</code> is the specified significance level. We will set
<code>alpha = 0.05</code>.</li>
<li>1 - <code>beta</code> is the minimal power that we require for our
drug development program. We will set <code>beta = 0.1</code>, meaning
that we require a power of 90%.</li>
</ul>
<p>As in the setting with normally distributed outcomes, the treatment
effect may be fixed (as in this example) or follows a prior distribution
(see <a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html">Fixed
or Prior</a>). Furthermore, all options to adapt the program to your
specific needs are also available in this setting (see <a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html">More
Paramters</a>).</p>
<p>Now that we have defined all parameters needed for our example, we
are ready to feed them to the package. We will use the function
<code><a href="../reference/optimal_binary.html">optimal_binary()</a></code>, which calculates the optimal sample size
and the optimal threshold value for a binary distributed outcome
variable.</p>
<div class="sourceCode" id="cb2"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="va">res</span> <span class="op">&lt;-</span> <span class="fu"><a href="../reference/optimal_binary.html">optimal_binary</a></span><span class="op">(</span>p0 <span class="op">=</span> <span class="fl">0.5</span>, p11 <span class="op">=</span>  <span class="fl">0.3</span>,               <span class="co"># probabilities of the unfavorable outcome</span></span>
<span>   n2min <span class="op">=</span> <span class="fl">20</span>, n2max <span class="op">=</span> <span class="fl">400</span>, stepn2 <span class="op">=</span> <span class="fl">4</span>,                   <span class="co"># define optimization set for n2</span></span>
<span>   rrgomin <span class="op">=</span> <span class="fl">0.7</span>, rrgomax <span class="op">=</span> <span class="fl">0.9</span>, steprrgo <span class="op">=</span> <span class="fl">0.01</span>,         <span class="co"># define optimization set for RRgo</span></span>
<span>   alpha <span class="op">=</span> <span class="fl">0.05</span>, beta <span class="op">=</span> <span class="fl">0.1</span>,                              <span class="co"># drug development planning parameters</span></span>
<span>   c2 <span class="op">=</span> <span class="fl">0.75</span>, c3 <span class="op">=</span> <span class="fl">1</span>, c02 <span class="op">=</span> <span class="fl">100</span>, c03 <span class="op">=</span> <span class="fl">150</span>,               <span class="co"># define fixed and variable costs for phase II and III,</span></span>
<span>   K <span class="op">=</span> <span class="cn">Inf</span>, N <span class="op">=</span> <span class="cn">Inf</span>, S <span class="op">=</span> <span class="op">-</span><span class="cn">Inf</span>,                            <span class="co"># constraints</span></span>
<span>   steps1 <span class="op">=</span> <span class="fl">1</span>, stepm1 <span class="op">=</span> <span class="fl">0.95</span>,  stepl1 <span class="op">=</span> <span class="fl">0.85</span>,             <span class="co"># treatment effect size categories as proposed by IQWiG (2016)</span></span>
<span>   b1 <span class="op">=</span> <span class="fl">1000</span>, b2 <span class="op">=</span> <span class="fl">2000</span>, b3 <span class="op">=</span> <span class="fl">3000</span>,                       <span class="co"># expected benefit categories</span></span>
<span>   w <span class="op">=</span> <span class="fl">0.3</span>, p12 <span class="op">=</span> <span class="fl">0.5</span>, in1 <span class="op">=</span> <span class="fl">30</span>, in2 <span class="op">=</span> <span class="fl">60</span>,                <span class="co"># prior (https://web.imbi.uni-heidelberg.de/prior/)</span></span>
<span>   gamma <span class="op">=</span> <span class="fl">0</span>,                                             <span class="co"># population structures in phase II and III</span></span>
<span>   fixed <span class="op">=</span> <span class="cn">TRUE</span>,                                          <span class="co"># choose if true treatment effects are fixed or random</span></span>
<span>   skipII <span class="op">=</span> <span class="cn">FALSE</span>,                                        <span class="co"># choose if skipping phase II would be an option</span></span>
<span>   num_cl <span class="op">=</span> <span class="fl">1</span><span class="op">)</span></span></code></pre></div>
</div>
<div class="section level3">
<h3 id="interpreting-the-output">Interpreting the output<a class="anchor" aria-label="anchor" href="#interpreting-the-output"></a>
</h3>
<p>After setting all these input parameters and running the function,
let’s take a look at the output of the program.</p>
<div class="sourceCode" id="cb3"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="va">res</span></span>
<span><span class="co">#&gt;         u RRgo  n2  n3   n  pgo sProg  p0  p1   K  K2  K3 sProg1 sProg2 sProg3</span></span>
<span><span class="co">#&gt; 1 1528.94 0.87 256 290 546 0.99  0.84 0.5 0.3 Inf 292 438   0.05   0.16   0.63</span></span>
<span><span class="co">#&gt;   steps1 stepm1 stepl1 alpha beta c02 c03   c2 c3   b1   b2   b3 gamma</span></span>
<span><span class="co">#&gt; 1      1   0.95   0.85  0.05  0.1 100 150 0.75  1 1000 2000 3000     0</span></span></code></pre></div>
<p>The program returns a total of thirteen values and the input values.
For now, we will only look at the most important ones:</p>
<ul>
<li>
<code>res$n2</code> is the optimal sample size for phase II and
<code>res$n3</code> the resulting sample size for phase III. We see that
the optimal scenario requires 256 participants in phase II and 290
participants in phase III.</li>
<li>
<code>res$RRgo</code> is the optimal threshold value for the
go/no-go decision rule. We see that we need a risk ratio of less than
0.87 in phase II in order to proceed to phase III.</li>
<li>
<code>res$u</code> is the expected utility of the program for the
optimal sample size and threshold value. In our case it amounts to
1528.94, i.e we have an expected utility of 152 894 000$.</li>
</ul>
</div>
</div>
<div class="section level2">
<h2 id="where-to-go-from-here">Where to go from here<a class="anchor" aria-label="anchor" href="#where-to-go-from-here"></a>
</h2>
<p>In this article we introduced the setting, when the outcome variable
is binary distributed. For more information on how to use the package,
see:</p>
<ul>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/introduction-to-drugdevelopR.html"><em>Introduction
to drugdevelopR:</em></a> See how the package works in a basic
example.</li>
<li>
<em>Different outcomes:</em> Apply it to <a href="https://sterniii3.github.io/drugdevelopR/articles/Time-to-event_outcomes.html">time-to-event
endpoints</a>.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/Interpreting_Output.html"><em>Interpreting
the rest of the output:</em></a> Obtain further details on your drug
development program.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/Fixed_and_prior_distributions.html"><em>Fixed
or prior:</em></a> Model the assumed treatment effect on a prior
distribution.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html"><em>More
parameters:</em></a> Define custom effect size categories. Put
constraints on the optimization by defining maximum costs, the total
expected sample size of the program or the minimum expected probability
of a successful program. Define an expected difference in treatment
effect between phase II and III. Skip phase II.</li>
<li>
<em>Complex drug development programs:</em> Adapt to situations with
<a href="https://sterniii3.github.io/drugdevelopR/articles/Bias_adjustment.html">biased
effect estimators</a>, <a href="https://sterniii3.github.io/drugdevelopR/articles/Multitrial.html">multiple
phase III trials</a>, multi-arm trials, or multiple endpoints.</li>
<li>
<a href="https://sterniii3.github.io/drugdevelopR/articles/More_Parameters.html"><em>Parallel
computing:</em></a> Be faster at calculating the optimum by using
parallel computing.</li>
</ul>
</div>
  </main><aside class="col-md-3"><nav id="toc"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p></p>
<p>Developed by Stella Preussler.</p>
</div>

<div class="pkgdown-footer-right">
  <p></p>
<p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.7.</p>
</div>

    </footer>
</div>

  

  

  </body>
</html>
